lifestyle.goodsciencing.com

Author: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

April 16, 2026
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

April 15, 2026
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

April 14, 2026
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

April 13, 2026
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

April 13, 2026
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

March 13, 2026
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

March 2, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

February 11, 2026